Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · IEX Real-Time Price · USD
0.00 (-0.02%)
At close: May 20, 2024, 3:59 PM
+0.026 (4.14%)
After-hours: May 20, 2024, 6:19 PM EDT

Alzamend Neuro Statistics

Total Valuation

Alzamend Neuro has a market cap or net worth of $4.36 million. The enterprise value is $4.08 million.

Market Cap 4.36M
Enterprise Value 4.08M

Important Dates

The last earnings date was Monday, March 25, 2024, after market close.

Earnings Date Mar 25, 2024
Ex-Dividend Date n/a

Share Statistics

Alzamend Neuro has 6.88 million shares outstanding. The number of shares has increased by 7.62% in one year.

Shares Outstanding 6.88M
Shares Change (YoY) +7.62%
Shares Change (QoQ) +7.47%
Owned by Insiders (%) 29.58%
Owned by Institutions (%) 5.24%
Float 4.84M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio n/a
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.16

Current Ratio 0.16
Quick Ratio n/a
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1,353.94

Financial Efficiency

Return on Equity (ROE) n/a
Return on Assets (ROA) -481.20%
Return on Capital (ROIC) n/a
Revenue Per Employee n/a
Profits Per Employee -$3.10M
Employee Count 4
Asset Turnover n/a
Inventory Turnover n/a


Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -91.88% in the last 52 weeks. The beta is 0.12, so Alzamend Neuro's price volatility has been lower than the market average.

Beta (1Y) 0.12
52-Week Price Change -91.88%
50-Day Moving Average 0.81
200-Day Moving Average 1.83
Relative Strength Index (RSI) 44.15
Average Volume (30 Days) 82,311

Short Selling Information

The latest short interest is 22,519, so 0.33% of the outstanding shares have been sold short.

Short Interest 22,519
Short Previous Month 14,505
Short % of Shares Out 0.33%
Short % of Float 0.47%
Short Ratio (days to cover) 0.51

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -12.39M
Pretax Income -12.40M
Net Income -12.40M
EBITDA -12.35M
EBIT -12.39M
Earnings Per Share (EPS) -$1.87
Full Income Statement

Balance Sheet

The company has $282,867 in cash and no debt, giving a net cash position of $282,867 or $0.04 per share.

Cash & Cash Equivalents 282,867
Total Debt n/a
Net Cash 282,867
Net Cash Per Share $0.04
Equity / Book Value -4.26M
Book Value Per Share -0.62
Working Capital -3.23M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$9.08 million and capital expenditures -$147,243, giving a free cash flow of -$9.23 million.

Operating Cash Flow -9.08M
Capital Expenditures -147,243
Free Cash Flow -9.23M
FCF Per Share -$1.31
Full Cash Flow Statement


Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Alzamend Neuro does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -7.62%
Shareholder Yield -7.62%
Earnings Yield -284.54%
FCF Yield -211.67%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus n/a
Analyst Count n/a
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on October 31, 2023. It was a reverse split with a ratio of 1:15.

Last Split Date Oct 31, 2023
Split Type Reverse
Split Ratio 1:15


Altman Z-Score n/a
Piotroski F-Score 1